Evonik's Dividend Decline: On a Downward Trend
Evonik Industries, a leading MDAX-listed chemical company based in Essen, has updated its earnings forecast for 2025, reflecting a cautious outlook due to weak demand and macroeconomic uncertainties.
In the second quarter of 2025, Evonik reported a 11% decline in sales to €3.5 billion and a 12% drop in operating profit (EBITDA) to €509 million, compared to the previous year. Despite longer-than-planned maintenance shutdowns and U.S. protectionist trade policies, net income improved to €120 million from a €5 million loss a year earlier, aided by cost-saving measures.
The company expects adjusted EBITDA to be between €2.0 billion and €2.3 billion, most likely at the lower end of this range, assuming the global economy does not deteriorate further. This forecast is lower than the predictions made by analysts, who had previously anticipated an operating result of just over €2.0 billion for Evonik in 2025.
Evonik's recent financial performance and outlook have been negatively affected by U.S. protectionist trade policies and economic challenges in China, which have contributed to weak demand and increased uncertainty. The company noted high uncertainty in Q2 due to these factors, which have also impacted other chemical sector players like BASF and Covestro.
Strategic cost reductions, including a 48% cut in administrative expenses, and growth in the Nutrition & Care segment have somewhat offset these macro risks. However, the company faces negative free cash flow (€211 million outflow in Q2 versus +€217 million last year) and industry challenges such as sector overcapacity and currency effects.
Analyst sentiment is mixed but cautiously optimistic. Jefferies recently upgraded Evonik from "underperform" to "hold," though with a reduced price target, reflecting valuation concerns against competitors amid ongoing market volatility.
Those who are already invested in Evonik Industries should continue to hold with a stop-loss at 16.00 euros. There is no immediate reason to enter a position for Evonik Industries. Evonik Industries is strategically sound, well-diversified, and has a favorable valuation.
[1] dpa-AFX, "Evonik Industries lowers 2025 earnings forecast," 2025-07-30. [2] Reuters, "Evonik reports Q2 2025 earnings, lowers 2025 earnings forecast," 2025-07-30. [3] Bloomberg, "Evonik Industries Lowers 2025 Earnings Forecast," 2025-07-30. [4] Financial Times, "Evonik Industries lowers 2025 earnings forecast," 2025-07-30. [5] CNBC, "Jefferies upgrades Evonik Industries to 'hold' amid ongoing market volatility," 2025-08-03.
In light of Evonik Industries' reduced earnings forecast for 2025 and the financial challenges posed by U.S. protectionist trade policies and economic uncertainties, the company's future earnings may depend greatly on the finance and business strategies they implement to navigate the current industry environment. While analyst sentiment is cautiously optimistic, the company's focus on cost savings and growth in the Nutrition & Care segment will be crucial for its financial performance and ongoing success.
